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Abstract
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure
has been linked to improved patient outcomes. In the era of direct-acting antivirals
(DAAs), HCV cure has become the goal, as defined by sustained virological response
12 weeks (SVR12) after completion of therapy. Historically, African-Americans have
had lower SVR12 rates compared to White people in the interferon era, which had
been attributed to the high prevalence of non-CC interleukin 28B (IL28B) type. Less
is known about the association between race/ethnicity and SVR12 in DAA-treated
era. The aim of the study is to evaluate the predictors of SVR12 in a diverse, single-
center Veterans Affairs population. We conducted a retrospective study of patients
undergoing HCV therapy with DAAs from 2014 to 2016 at the VA Greater Los
Angeles Healthcare System. We performed a multivariable logistic regression analy-
sis to determine predictors of SVR12, adjusting for age, HCV genotype, DAA regi-
men and duration, human immunodeficiency virus (HIV) status, fibrosis, nonalcoholic
fatty liver disease (NAFLD) fibrosis score, homelessness, mental health, and adher-
ence. Our cohort included 1068 patients, out of which 401 (37.5%) were White
people and 400 (37.5%) were African-American. Genotype 1 was the most common
genotype (83.9%, N = 896). In the adjusted models, race/ethnicity and the presence
of fibrosis were statistically significant predictors of non-SVR. African-Americans
had 57% lower odds for reaching SVR12 (adj.OR = 0.43, 95% CI = 1.5-4.1) com-
pared to White people. Advanced fibrosis (adj.OR = 0.40, 95% CI = 0.26-0.68) was
also a significant predictor of non-SVR. In a single-center VA population on DAAs,
Abbreviations: BMI, body mass index; CI, confidence interval; CYP, cytochrome P450; DAAs, direct-acting antivirals; Fib4, fibrosis-4; HCC, hepatocellular carcinoma; HCV, hepatitis C virus;
HIV, human immunodeficiency virus; ICD, international classification of diseases; MPR, medication procession ratio; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; RNA, ribonucleic
acid; SVR12, sustained virological response at 12 weeks.
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African-Americans were less likely than White people to reach SVR12 when adjust-
ing for covariates.
K E YWORD S
Adherence, direct-acting antivirals, direct drug acting, drug metabolism, ethnicity, Hepatitis C,
medication procession ratio, polymorphisms, race, racial disparity, sustained virological
response 12, Veterans Affairs
1 | INTRODUCTION
Hepatitis C remains a burden with at least 5.2 million infected peo-
ple worldwide.1 Long-term infection can lead to complications
including cirrhosis, hepatocellular carcinoma, and death.2 Eradication
of HCV has become a focus given that sustained virological response
(SVR) has been associated with reversal of hepatic fibrosis and
decreased rates of HCC.3,4
Historically, race has played a major role in chronic hepatitis C
rates and treatment responses with African-Americans being dispro-
portionately affected.5,6 Host immune responses largely explained
these differences as African-Americans were more likely to harbor
the non-CC interleukin IL28B genotype which affected their
response to pegylated interferon.7,8 More recently, new direct-acting
antivirals (DAAs) have revolutionized hepatitis C therapy given their
ease of administration, tolerability and reported sustained virological
response at 12 weeks (SVR12) with rates in the 90s, depending on
the extent of liver fibrosis and genotype.9 Despite these strides,
racial differences in treatment outcomes remain. In large cohorts of
patients with genotype 1 treated with sofosbuvir/ledipasvir with or
without ribavirin, Africans-Americans were shown to have higher
rates of relapse, although these differences disappeared after
extending therapy from 8 to 12 weeks.10 These data were corrobo-
rated in a larger Veterans Affairs cohort where African-American
patients treated with 12 weeks of therapy instead of 8 reached
SVR12 rates similar to their White counterparts.11 More recently, Su
and colleagues demonstrated that African-Americans in the VA trea-
ted with DAAs have lower SVR rates than White Veterans. In a mul-
tivariable regression model, adjusting for factors that can affect SVR,
the adjusted odds ratio for African-Americans was 0.77 for reaching
SVR compared to White people (95% CI = 0.69-0.87), where 29% of
the population was African-American (N = 6171).12 Whether these
race-based differences in SVR, particularly with abbreviated regi-
mens, both in the interferon and DAA eras are due to genetic or
other socioeconomic factors remains to be elucidated.
The disproportionate HCV infection rates in African-Americans
and higher risk of developing HCC independently of fibrosis under-
scores the importance of understanding why these differences
exist.13,14 The aim of our study is to address if racial/ethnic differ-
ences in SVR12 are observed in a large and ethnically diverse single-
center Veterans Affairs cohort treated with DAAs or all genotypes,
when controlling for HCV treatments, extent of fibrosis, and treat-
ment adherence.
2 | MATERIALS AND METHODS
2.1 | Data source
This was an observational retrospective study of all HCV-infected
patients treated at the VA Greater Los Angeles Healthcare System
within the Corporate Data Warehouse for a diagnosis of chronic
hepatitis C by the International Classification of Diseases, ICD-9 or
ICD-10, coding. Data were extracted from January 1, 2014 to
December 31, 2016 and included: baseline demographic and clinical
characteristics, medication, laboratory results, outpatient visits, and
previous diseases/diagnoses.
2.2 | Study population
The study population consisted of consecutive HCV-infected
patients who received DAA therapy at VA Greater Los Angeles
Healthcare System. Patients without SVR data available 12 or more
weeks following antiviral therapy were excluded from analysis. All
genotypes 1-6 were included. Choice of DAA regimen was at
the discretion of the provider. On-treatment and posttreatment
monitoring followed an established protocol that included serum
SVR evaluation every 2-4 weeks.
2.3 | Sustained virological response
The primary outcome of our study was SVR12, which was defined
as an undetectable HCV RNA (<15 IU/mL) 12 weeks or beyond the
conclusion of treatment.15
2.4 | Baseline characteristics
Baseline demographic variables obtained at the initiation of therapy
included: age, self-reported race and ethnicity; HCV genotype; non-
alcoholic fatty liver (NAFLD) fibrosis score (<1.455 being unlikely
to have advanced NAFLD fibrosis vs >0.676 being predictive of
advanced NAFLD-associated fibrosis)16; the Fibrosis-4 (Fib4; which
will be referred to as advanced fibrosis from here forward), as a mar-
ker of advanced liver disease using the formula (age x aspartate
aminotransferase)/(platelets X alanine aminotransferase1/2)17; body
mass index (BMI) (≥30 kg/m2 and <30 kg/m2); HIV status; and HCV
treatment status (na€ıve or experienced). For race and ethnicity, we
used a single variable that combines concepts of race and ethnicity
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into five mutually exclusive categories for race/ethnicity: non-Hispa-
nic White, non-Hispanic Black (African-Americans), Hispanics, Asians,
and Unknown/Other. The presence of diabetes and its complications
were determined by ICD-9 (250.00-250.92) and ICD-10 codes, as
were diagnoses of hypertension, hyperlipidemia, HIV, and AIDS with
their complications. Psychiatric disorders, both organic and nonor-
ganic (associated with substance abuse or not) were included in our
analysis as was substance abuse and homelessness.
2.5 | Medication adherence
Patient adherence was assessed by calculating the medication pro-
cession ratio (MPR) since this has been a validated method to deter-
mine adherence.18 MPR was defined by the total number of pills
supplied over the total number of pills expected to be dispensed by
the pharmacy department based on length of treatment regimen and
genotype. For purposes of simplicity, “MPR” will be defined and
described as “adherence” from here onward.
2.6 | Statistical analysis
Demographic data which included sex, race/ethnicity, DAA regimen,
body mass index (BMI), advanced fibrosis, and genotype were sum-
marized with frequencies and chi-square tests for comparisons. We
conducted multivariable logistic regression analysis to model predic-
tors of SVR12. A priori covariates selected for the model were age,
race/ethnicity, genotype, treatment regimen, treatment length, being
treatment na€ıve, HIV status, advanced fibrosis, NAFLD fibrosis score,
and adherence as defined by adherence. Age and adherence were
continuous variables in the analysis. To analyze the adherence data
further, we stratified adherence into the following groups: ≥90%,
80%-89%, 60%-79%, and <60%. In addition to using adherence as a
continuous variable we also performed regression models with MRP
with the defined groups as a categorical covariate. Prior to regres-
sion analyses, we tested for multiple collinearity, and no covariates
were collinear as defined as a variance inflation factor of less than
10. Separate logistic multivariable regressions models were used to
model SVR predictors in the African-American subgroup by assessing
treatment length of 8- versus 12-week treatment, removing what is
now considered suboptimal therapies (sofosbuvir/simeprevir 
ribavirin and sofosbuvir/ribavirin). We also performed regression
models by race/ethnicity, genotype, and adherence on SVR12.
This study was approved by the Institutional Review Board and
Research and Development Committee at the VA Greater Los Ange-
les Healthcare System.
3 | RESULTS
3.1 | Baseline characteristics and treatment
regimens
Of the 1204 patients meeting the inclusion and exclusion criteria,
1068 patients were included for analysis based on having complete
demographic and follow-up data. Baseline characteristics of the
cohort are presented in Table 1. Males comprised 97% of the
study cohort, consistent with gender demographics within the VA
system. The mean age was 61.8 (SE  0.2). White people and Afri-
can-Americans were equally represented at 37.8% of the popula-
tion. Genotype 1 (1a and 1b) was the most common genotype in
83.9% of patients (N = 896), followed by genotype 2 (7.9%,
N = 84) and genotype 3 (6.9%, N = 74). None of the patients had
genotype 5. Of all patients, 35.4% were considered to have
advanced liver disease as defined by a Fib4 > 3.25. A minority of
patients were HIV positive (3%, N = 35). The majority of patients
were treatment na€ıve at the time of DAA initiation at 79.5%
(N = 849).
DAA treatment regimen allocations for all patients and the cor-
responding SVR12 for each genotype are summarized in Table 2.
The most common regimen was sofosbuvir/ledipasvir  ribavirin,
which occurred for 47.8% of the population. Since the study cohort
included patients started on antiviral therapy from January 1, 2014,
our data also include older antiviral regimens such as sofosbuvir/
simeprevir (17.5%, N = 187), sofosbuvir/simeprevir  ribavirin
(0.7%, N = 7), and sofosbuvir/ribavirin (9.8%, N = 105). Our data
also include a subgroup of African-Americans patients who only
received 8 weeks of therapy instead of 12 (N = 159) based on pre-
treatment viral level. These patients were treated before 2015 and
prior to recommendations to use 12-week regimens in African-
Americans.10
TABLE 1 Demographics of study population
Demographic N = 1068
Age in years, mean 61.8
SVR, % 87.0
Race/ethnicity, % (N)
White people 37.5 (400)
African-American 37.5 (401)
Hispanic 15.1 (161)
Asian 0.7 (7)
Other/Unknown 21 (9.3)
Genotype 1 (a & b), % (N) 83.9 (896)
Treatment na€ıve, % (N) 79.5 (849)
BMI > 30, % (N) 33.5 (358)
Advanced fibrosis, % (N) 35.4 (462)
HIV positive, % (N) 3.3 (35)
Homelessness, % (N) 22 (236)
Substance abuse, % (N) 27.9 (298)
History of psychiatric disorder, % (N) 58.5 (625)
Medical procession ration, % (N)
<60% 5.3% (57)
60-79% 0.5% (5)
80-89% 0.2% (2)
≥90% 94% (1004)
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3.2 | Predictors of SVR12
Predictors of SVR12 from adjusted regression models are summa-
rized in Table 3. There were two clinically significant negative pre-
dictors of SVR12: African-American race/ethnicity (aOR = 0.43;
95% CI = 0.27-0.69) and advanced liver disease (Fib4 score >3.25)
(aOR = 0.4; 95% CI = 0.26-0.68). Covariates that did not affect
SVR12 included age, genotype, HIV status, advanced NAFLD fibro-
sis score, BMI ≥ 30 kg/m2, and whether the patient was treatment
na€ıve or experienced.
3.3 | SVR12 by race/ethnicity
SVR12 differences by race/ethnicity were also observed. African-
Americans reached SVR12 85% of the time, while White people had
SVR rates of 89% and Hispanics of 83%. When older therapies
(sofosbuvir/simeprevir, sofosbuvir/simeprevir  ribavirin, sofosbuvir/
ribavirin) were excluded from the analysis, African-Americans
reached SVR12 87.8% of the time, while White people and Hispan-
ics achieved SVR12 rates of 92.4% and 88.7%, respectively. Hispan-
ics had an adjusted OR of 0.75 (95% CI = 0.43-1.31); Asians of 0.61
(95% CI = 0.67-5.43); and other/unknown race/ethnicity of 0.67
(95% CI = 0.13-3.37).
3.4 | SVR12 in African-Americans by treatment
duration subgroup
Given previously published data suggesting that African-American
patients require 12 weeks of therapy regardless of baseline viral
load, we further investigated SVR12 rates for African-Americans
when stratifying by duration of treatment (8 weeks and
12 weeks).10,11 Only 159 African-American patients were treated for
8 weeks of therapy given the recent change in clinical practice. The
adjusted odds ratio for SVR12 for all genotypes in the 8-week group
was 0.34 (95% CI = 0.09-1.29) compared to 0.4 (95% CI = 0.25-
0.63) in the 12-week treatment group (N = 1043).
There were 746 African-American patients who were treated
with DAA regimens other than sofosbuvir/ledipasvir  ribavirin
and sofosbuvir/ribavirin. In this subgroup, the adjusted OR for
SVR12 among African-Americans was 0.45 (95% CI = 0.25-0.81),
consistent with a significantly lower SVR12 for those only using
optimal therapy when compared to those on obsolete therapies.
However, when adherence, as defined by MPR, was included in
the model, the adjusted OR was 0.47 (95% CI = 0.21-1.07), miti-
gating the effect. When adjusting for homelessness, substance
abuse, and mental health disorders (N = 306), only homelessness
TABLE 2 Treatment regimen allocation and SVR12 rates for all
patients and genotypes
Treatment regimen by genotype
SVR12, % (N)
Genotype 1 1a 1b
Sofosbuvir/ledipasvir 95.0 (314) 90.0 (116)
Sofosbuvir/ledipasvir/ribavirin 87.2 (89) 92 (27)
Sofosbuvir/ribavirin 100.0 (1) 85.5 (1)
Sofosbuvir/simeprevir 78.0 (138) 100.0 (57)
Sofosbuvir/simeprevir/ribavirin 100.0 (8) 100.0 (1)
Paritaprevir/ritonavir/ombitasvir
+ dasabuvir
100.0 (1) 91.5 (47)
Paritaprevir/ritonavir/
ombitasvir + dasabuvir/ribavirin
83.6 (152) 91.5 (50)
Grazoprevir/elbasvir 100.0 (1) 100.0 (8)
Genotype 2
Sofosbuvir/ribavirin 77.8 (97)
Sofosbuvir/ledipasvir/ribavirin 100.0 (1)
Genotype 3
Sofosbuvir/ledipasvir 100.0 (1)
Sofosbuvir/ledipasvir/ribavirin 82.1 (43)
Sofosbuvir/ribavirin 61.1 (20)
sofosbuvir/daclatasvir 83.3 (7)
Sofosbuvir/daclatasvir/ribavirin 81.8 (13)
Genotype 4
Sofosbuvir/ledipasvir 100.0 (8)
Sofosbuvir/ribavirin 100.0 (3)
Paritaprevir/ritonavir/
ombitasvir + dasabuvir/ribavirin
100.0 (1)
Paritaprevir/ritonavir/
ombitasvir/ribavirin
100.0 (2)
Genotype 6
Sofosbuvir/ledipasvir 100.0 (1)
SVR12, sustained virological response at 12 weeks.
TABLE 3 Odds ratios for SVR12 for all patients
Patient characteristic
Unadjusted Adjusted
OR 95% CI OR 95% CI
African-American
(ref. White people)
0.77 0.54-1.11 0.43 0.27-0.69
Age 1.02 1.00-1.05 1.04 1.00-1.07
Genotype 2 (ref.
genotype 1)
0.5 0.29-0.88 2.47 0.25-24.5
Treatment Na€ıve
(ref. treatment
experienced)
1.44 0.95-2.17 1.46 0.90-2.37
Advanced fibrosis
(ref. Fib4 < 3.25)
0.4 0.28-0.58 0.40 0.26-0.68
BMI ≥ 30 (ref.
BMI<30 kg/m2)
0.9 0.62-1.31 1.18 0.79-1.78
HIV positive (ref.
HIV negative)
1.44 0.43-4.8 1.77 0.48-6.54
MPR 80-89% (ref. ≥90%) 0.15 0.01-2.37 a a
MPR 60-79% (ref. ≥90%) 0.04 0.004-0.32 <0.1 0
MPR <60% (ref. ≥90%) 0.02 0.01-0.05 0.01 13-166
aOmitted from the analysis given low number of patients (n=2).
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affected SVR12 rates among African-Americans (aOR = 0.39; 95%
CI = 0.19-0.81).
3.5 | SVR12 in genotype 1 patients
Given the heterogeneity of our patient population in genotype and
therapies, as well as the observation that genotype 3 is more diffi-
cult to eradicate,19 we performed subanalyses on patients with only
genotype 1 disease (1a and 1b) (N = 872). Similar to the larger
cohort, African-American race/ethnicity was a significant predictor
for non-SVR12 with an adjusted OR of 0.48 (95% CI = 0.29-0.80).
When older therapies were excluded (N = 69), being African-Ameri-
can race/ethnicity remained a significant predictor with an adjusted
OR of 0.47 (95% CI = 0.23-0.82). When adherence was included in
the model, African-American race/ethnicity was not a significant pre-
dictor (aOR = 0.60; 95% CI = 0.31-1.17). When addressing SVR12
only in the African-American subgroup treated for genotype 1
(N = 358), the only predictor of SVR12 failure was advanced liver
disease (aOR = 0.35; 95% CI = 0.12-0.97).
4 | DISCUSSION
This study demonstrates that in a large ethnically diverse commu-
nity-based Veterans Affairs practice, SVR12 rates for chronic hepati-
tis C are influenced by race/ethnicity and advanced liver disease,
which corroborates previously published data.10,12,20 In our cohort,
the lower SVR rates observed in African-Americans relative to White
people is persistent despite at least 12 weeks of therapy even when
only using current “optimal” therapies. One important consideration
in our analysis was the effect of adherence by measures of MPR in
an ethnically diverse population treated with direct-acting antivirals,
which has not been evaluated in detail previously. We find that
adherence explains some of these differences. These data suggest
potential underlying biological differences between White people
and African-Americans in medication response.
While adherence and medication tolerability are not a concern in
well-resourced large clinical trials, they can be more difficult to mea-
sure in real-world effectiveness data for chronic hepatitis C treat-
ment. In 2007, Backus and colleagues assessed SVR12 rates in a
Veterans Affairs cohort during the interferon era and demonstrated
adherence, as defined by MPR, to be a predictor of SVR success.
Patients with adherence of 90% or greater reached SVR 88% of the
time. There was a clear threshold where any adherence less than
80% negatively impacted SVR, resulting in SVR12 rates of only
8%.20 More recently in 2017, Louie and colleagues assessed real-
world effectiveness of SVR12 with the use of DAAs in the Kaiser
Permanente Southern California health care system. Although Afri-
can-Americans only represented 8% of their population (N = 17),
adherence was also a predictor of success with an adjusted OR of
2.28 if it reached 80% or higher.21 Our study demonstrated similar
findings. We find that patients with adherence rates of <90% did
not reach SVR12. Adherence appeared to attenuate the association
between race/ethnicity and SVR12, thus explaining some of the dif-
ferences observed, although biological causes have not been
addressed.
One potential biological explanation for these observations is
differences in drug metabolism, driven by the patients’ genetic back-
ground. Drug metabolism differences have been described to exist
between African-Americans and White people. Although some of
these differences have been attributed to environmental factors
such as diet and concomitant medications, intrinsic host factors such
as genetic variability and gene polymorphisms in drug metabolizers
such as CYP2D6 and CYP2C19 have also been described.22,23
Understanding genetic polymorphisms in African-Americans and elu-
cidating their mechanism of action, namely in the IL28B gene also
offered great advances in understanding the underlying genetic dif-
ferences between African-Americans and White people in the inter-
feron era.7,24 Other genetic differences such as the variant in
HAVCR1 gene variant (rs6880859) were also subsequently identi-
fied.25 Although the polymorphisms and genetic differences listed
above have not been shown to affect SVR12 with DAAs, such
undiscovered genetic polymorphisms could explain these findings.
The effects of genetic variants on SVR in the DAA era have not
been addressed systematically other than to assess patterns of resis-
tance.26 The previous findings that extending therapy in African-
Americans from 8 to 12 weeks to reach similar SVR12 to White
people, also points to potential biological differences between dif-
ferent races and ethnicities. To address this, Large Genome Wide
Association Studies (GWAS) or comparing genotypes in African-
Americans and White people who reached and did not reach SVR
are needed.
Another consideration in our analysis is the effect of genotype
on each race/ethnicity. Although we did not stratify our data by
genotype for each race, it is possible that some of the differences
observed were driven by the virus genotype. For example, the aOR
for genotype 2 dramatically improved (0.5-2.5) after adjusting for
other covariates. All patients treated with sofosbuvir/ribavirin were
considered “sub-optimal” with SVR12 rates of 77.8%. Of that group,
11 patients were African-American. To address this further, SVR12
in African-Americans would have to be evaluated with new and “op-
timal” therapies.
While our study highlights important differences in DAA
responses by race/ethnicity, there are limitations. Given the pre-
dominance of males in the VA population, our data may not be
generalizable to female patients. Similarly, the small number of HIV-
confected patients in our cohort cannot provide conclusive observa-
tions about SVR12 rates in this group. The VA Greater Los Angeles
Healthcare System covers a large geographical region within the
Los Angeles area. It remains unclear at this time if the lower adher-
ence rates observed in African-Americans is associated with geo-
graphical regions. Our facilities offer telemedicine and remote
access care which was taken into account in our adjusted model
(data not shown), thus making access to care an unlikely etiology.
Another possibility for the large MRP effects in African-Americans
is medication tolerability/side effects, which could also be related
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to the intrinsic metabolism of these medications. Ideally, metabolite
levels would have been checked to further assess this; however,
given the retrospective nature of our study, this was not addressed.
Examining the true associations between socioeconomic status and
adherence can be more challenging and would require a root-cause
analysis.
In conclusion, we present a large, ethnically and medically
heterogeneous population within the Veterans Affairs System and
their SVRs rates in the DAA era. Although our data demonstrate the
importance of racial/ethnic differences, the true etiology of these
differences remains unclear, which can be further explored in
prospective studies where drug levels and patient genetics are taken
into account.
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